Introduction
============

Primary care physicians provide all or at least part of the health care for 80% of the more than 20 million Americans with recognized and unrecognized chronic obstructive pulmonary disease (COPD) ([@b35-copd-3-311]; [@b23-copd-3-311]). For those with recognized COPD, current management is frequently incompatible with recommended care ([@b1-copd-3-311]; [@b21-copd-3-311]; [@b38-copd-3-311]) For those who have unrecognized COPD, opportunities to improve their functional status, quality of life, and prevention of exacerbations are missed by failure to recognize the disease ([@b43-copd-3-311]; [@b24-copd-3-311], [@b25-copd-3-311]; [@b56-copd-3-311]; [@b32-copd-3-311]).

Among the barriers that may slow the implementation of evidence-based COPD management are ambiguous and divergent US recommendations for COPD screening ([@b40-copd-3-311]; [@b27-copd-3-311]; [@b8-copd-3-311]; [@b53-copd-3-311]; [@b26-copd-3-311]; [@b54-copd-3-311]). The lack of well recognized US primary care guidelines for the management of diagnosed COPD is another potential barrier to an aggressive primary care approach to COPD. The international Global Initiative for Obstructive Lung Disease (GOLD) guidelines ([@b21-copd-3-311]; [@b28-copd-3-311]), the International Primary Care Respiratory Group (IPCRG) COPD guidelines ([@b31-copd-3-311]), and the American Thoracic Society/European Respiratory Society COPD guidelines ([@b1-copd-3-311]) have received limited exposure among US primary care physicians, especially in comparison with guidelines for the other major obstructive lung disease, asthma.

As part of its effort to collaborate with the National Heart Lung and Blood Institute's (NHLBI) COPD public awareness campaign ([@b21-copd-3-311]), the American Academy of Family Physicians (AAFP) included COPD as part of its annual clinical focus on five chronic diseases in 2006--2007 and sponsored COPD continuing medical education (CME) sessions in three major US cities in the summer of 2006. In conjunction with those sessions, COPD-related surveys were distributed to all attendees. Information from these surveys was used to better focus future education programs and as a comparison for similar data from generalists practicing in other countries such as the United Kingdom and the Netherlands where COPD management has received greater primary care emphasis ([@b37-copd-3-311]; [@b36-copd-3-311]).

Methods
=======

The attendees of three AAFP sponsored CME programs held in Raleigh, NC, Costa Mesa, CA and Chicago, IL were asked to complete a brief survey during the 10 minutes immediately prior to a 70-min talk on COPD diagnosis and management given by one of the authors (BPY). The completed surveys were collected during the first 15 minutes of the talk so that little of the information in the talk should have influenced the attendees' responses to the surveys. We therefore believe that the information provided is based on attendees' prior knowledge of COPD, not on knowledge gained during the lecture.

The overall response rate to the survey varied slightly by site from 155 (70%) in Chicago, to 170 (55%) in Costa Mesa, and 130 (57%) in Raleigh. The total number of useable surveys was 284 out of 455 possible (62% overall).

The survey included questions on demographic information: specialty, age (divided into 5 categories), gender, and length of time in practice (in 4 categories). Additional practice-related information included: practice site (rural/urban/suburban), practice size (solo, small group -- up to 5, medium -- 6 to 10 and over 10), and practice type (single or multi-specialty).

Specific questions about COPD included queries about which guidelines the respondent used for COPD, barriers to COPD diagnosis, characteristics used to make a diagnosis of COPD and testing done for COPD. Two questions about rates of smoking in patients in the community and access to smoking cessation services were included.

The last set of questions asked about attitudes and beliefs related to COPD including differentiation from asthma, effectiveness of treatment for COPD symptoms, increasing longevity, decreasing exacerbations and the value and accessibility of pulmonary rehabilitation. The final two questions addressed the expected gender and age of symptom-onset of COPD patients.

Data were entered into an Excel (Microsoft, Redmond, WA) spreadsheet and first analyzed using simple descriptive statistics to obtain frequencies of responses overall. Responses were stratified in different groupings including by site of program (eg, region of country, n = 3), and by level of training (physician versus nurse practitioner \[NP\] and physician's assistant \[PA\]). Statistical comparisons used chi-square and Mantel Haenzel testing. Regression models were developed for use of spirometry testing for diagnosis of COPD that included respondent's age, gender, level of training, region of country, and time since graduating as the independent variables. Similar models were developed for use of reversibility testing and use of COPD guidelines.

Results
=======

The attendee respondents whose data were included in the analysis (n = 278) were a combination of family physicians (n = 178, 63% of respondents), and nonphysician clinicians including NPs and PAs (n = 100, 35%). Four respondents identified themselves as "other" and two others who did not answer the question were excluded from further analysis. The median age was 40--49 years and over half (57%) were women ([Table 1](#t1-copd-3-311){ref-type="table"}).

The most commonly reported "COPD" guidelines used were the GOLD and ATS/ERS guidelines (n = 133, 47%, either one or both). Sixty two people (21%) reporting using none and 27 (10%) stated that they did not know such guidelines existed. Thirty one people (11%) checked that they used the NAEPP guidelines for COPD. These are asthma guidelines that do not deal with COPD. Lack of awareness of COPD guidelines (didn't know, plus those reporting use of NAEPP guidelines for COPD) varied by site of the talk, the qualifications of the health professional, their age, and whether or not they had spirometry equipment in their office ([Table 2](#t2-copd-3-311){ref-type="table"}).

Respondents were asked to mark all barriers they experience in diagnosing COPD. The most commonly listed barriers to the diagnosis of COPD are shown in Table 3 and include lack of symptoms, failure of patient to report symptoms as well as the impact of multiple chronic conditions in people with COPD. About one in four respondents admitted to inadequate knowledge and training about COPD diagnosis and management. Some perceived barriers such as the presence of multiple morbidities (NP/PAs (64%) vs MDs (45%); p = 0.01) and lack of training (NPs/PAs 33% vs M.D. (22%); p = 0.06) varied by level of health professional ([Table 4](#t4-copd-3-311){ref-type="table"}).

Frequently reported barriers also varied by region of the country. Attendees in Chicago were significantly less likely to report patient failure to report symptoms (37%) compared with attendees in Costa Mesa, CA and Raleigh, NC (54% and 55%, respectively; p = 0.01). Concerns about training were more common among attendees from Costa Mesa, CA (35%) than among those from Raleigh, NC (21%) (p = 0.01). However, reported use of spirometry did not vary by region ([Table 2](#t2-copd-3-311){ref-type="table"}).

While a history of smoking, cough, and dyspnea were all considered important in diagnosing COPD, spirometry testing results was the most commonly listed factor for diagnosing COPD ([Table 3](#t3-copd-3-311){ref-type="table"}). While 76% of the attendees stated that they used spirometry for COPD diagnosis and 52% (n = 148) said they had spirometry testing available in their office, only 31% (n = 89) said they used spirometry for all COPD diagnoses. Only 91 (32%) respondents (38% of MDs vs 23% of NPs/Pas; p = 0.01) reported use of reversibility testing for COPD diagnosis (See [Table 2](#t2-copd-3-311){ref-type="table"}).

Other "tests" used for diagnosing COPD included chest x-ray, a trial of bronchodilators and a trial of oral steroids ([Table 2](#t2-copd-3-311){ref-type="table"}). One in five, 56 (20%) reported referring all or most COPD patients to a lung specialist. Nineteen of the 278 (7%) reported regular use of alpha-one antitrypsin levels in testing COPD patients.

About one third of the attendees reported that the differentiation between asthma and COPD was difficult (n = 108, 38%) while over three-quarters, 78%, stated that COPD was primarily a disease of men and over half (61%) said that the COPD generally started at or after age 60.

While only 6% of the respondents reported that "lack of adequate treatment for COPD" was a barrier to diagnosis of COPD, few were optimistic about the value of COPD treatments. Overall, 15% stated that COPD treatment was somewhat or very useful for improving symptoms, and 3% thought that treatment was useful or very useful for decreasing the risk of exacerbations yet 13% stated that they thought COPD treatment could increase longevity. Beliefs about the value of COPD treatments did not vary significantly by site or training level.

Pulmonary rehabilitation was available to 32% of the attendees but only 3% thought rehabilitation was useful or very useful for COPD patients with another 16% saying they are neutral about the benefits of pulmonary rehabilitation. Beliefs about the value of pulmonary rehabilitation did not vary by site although pulmonary rehabilitation services had significantly higher availability for respondents in Costa Mesa, CA and Chicago, IL than in Raleigh, NC (32% and 28% vs 5%, respectively, p = 0.01).

Use of GOLD or ATS/ERS guidelines, use of broncho-dilator reversibility or spirometry testing in COPD diagnosis were examined for associations with demographic and office characteristics through multivariable logistic regression. Few associations were found. In particular, no significant associations were found with age, gender, experience, size of practice, or size of local population. MD's were more likely than NP/PAs to use bronchodilator reversibility in diagnosis (OR = 2.1, p = 0.005). Spirometry was more likely to be used in diagnosis when the office had a spirometer (OR = 3.7, p \< 0.0001). And GOLD or ATS guidelines were more likely to be used when the office had a spirometer (OR = 2.4, p = 0.002).

Discussion
==========

The health professionals attending these conferences report that almost half of them used either the GOLD or ATS/ERS guidelines for COPD diagnosis and management. Most of the other attendees (40%) were unaware of any COPD care guidelines or stated that they used the NAEPP (asthma) guidelines for COPD management. Even without use of guidelines, almost three-quarters of the attendees stated they used spirometry to diagnosis COPD with only about one third reporting inclusion of pre- and post-bronchodilator testing to make the diagnosis. This suggests that two-thirds do not consider lack of reversibility a necessary criteria for COPD diagnosis. This is comparable with awareness of COPD guidelines but higher reported COPD guideline and spirometry use than reported by [@b6-copd-3-311].

The attendees expressed considerable pessimism in the ability of medical therapy to improve symptoms or prevent exacerbations. Yet 15% felt that COPD therapy could improve longevity. These results suggest significant opportunities for education and improvements in use of tools to improve COPD recognition and management.

The reported use of spirometry among these attendees was higher than has been reported among family physicians in previous studies ([@b18-copd-3-311]; [@b17-copd-3-311]; [@b16-copd-3-311]; [@b13-copd-3-311]; [@b20-copd-3-311]; [@b29-copd-3-311]; [@b52-copd-3-311]; [@b33-copd-3-311]). It is possible that this is due to the large metropolitan communities in which these presentations were given, the presence of nonphysician clinicians who worked in specialty departments in primary care offices or to an increase acceptance of the value and importance of spirometry over the past 5 to 8 years. Several recent publications have supported the availability and positive impact of spirometry testing in family or general practices ([@b39-copd-3-311]; [@b46-copd-3-311]; [@b9-copd-3-311]; [@b8-copd-3-311]; [@b51-copd-3-311]; [@b47-copd-3-311]; [@b54-copd-3-311]). Since COPD was only one of five topics covered during these day-long sessions, it seems illogical to assume that all attendees had a special interest in COPD.

Less than half of the physicians and other clinicians who say they use spirometry to diagnose COPD reported they included reversibility or post bronchodilation assessment in the diagnostic evaluation. This is not consistent with COPD guidelines that list the lack of significant reversibility as a hallmark and part of the definition of COPD ([@b1-copd-3-311]; [@b21-copd-3-311]; [@b28-copd-3-311]).

About half of the physicians and other clinicians expressed concern that their patients fail to report COPD-related symptoms even though most respondents said they used symptoms of dyspnea with activity or at rest to diagnose COPD. This concern echoes that of other physicians around the world. To deal with this concern, several questionnaire-based COPD screening tools have been developed and tested in general practice patients ([@b19-copd-3-311]; [@b50-copd-3-311]; [@b44-copd-3-311]). Most of these surveys query patients about chronic productive cough, shortness of breath with exercise, increasing exercise intolerance, and smoking behavior. The need for these questionnaires is based on the premise that patients are often not forth-coming about symptoms and that without tools physicians and other clinicians often fail to ask about specific symptoms ([@b19-copd-3-311]; [@b50-copd-3-311]; [@b22-copd-3-311]; [@b44-copd-3-311]). The recent and ongoing NHLBI public awareness campaign is also based on this premise and uses many formats and types of media to help raise awareness of symptoms that patients should report to their physician or other clinician (see [www.COPD-medications](www.COPD-medications). gov, [www.COPD-guidebook.gov](www.COPD-guidebook.gov)).

The depth of the pessimism about the outcome of COPD treatment was disappointing. Primary care physicians often report cases of patients diagnosed with COPD whom the physician was unable to "help" except with terminal illness planning. Although some pessimism may be appropriate, it was surprising and inconsistent with reported data, that over 84% of health care professionals reported that they felt pharmacotherapy had no effect on COPD symptom reduction or reduction of exacerbations ([@b4-copd-3-311]; [@b12-copd-3-311]; [@b49-copd-3-311]; [@b41-copd-3-311]; [@b5-copd-3-311]; [@b3-copd-3-311]; [@b14-copd-3-311]; [@b30-copd-3-311]; [@b11-copd-3-311]). In addition, the attitude toward and use of pulmonary rehabilitation was very low. While availability was limited (32% reported availability) use was even lower. Recent data clearly shows the benefits of pulmonary rehabilitation ([@b42-copd-3-311]; [@b45-copd-3-311];Birnbaum and Carlin 2008). Additionally, education regarding the components and benefits of pulmonary rehabilitation and better reimbursement opportunities for these services could increase its inclusion in COPD management by primary care physicians. Conversely, the 15% of respondents who reported that COPD improved longevity may be over-optimistic. The optimism might be explained by attendees including smoking cessation and oxygen therapy in their group of COPD treatments that increase longevity ([@b2-copd-3-311]).

COPD is not a disease of men and often begins before age 60, unlike the beliefs expressed by over 60% of the attendees. Beginning in 2000, more women than men die each year of COPD ([@b10-copd-3-311]; [@b34-copd-3-311]) and COPD often begins in the patient's 40s or 50s. Early symptoms may go unnoticed including the early changes in activity levels and exertion that are the adaptations made to deal with early COPD ([@b15-copd-3-311]; [@b19-copd-3-311]; [@b31-copd-3-311]; [@b44-copd-3-311]; [@b21-copd-3-311]; [@b28-copd-3-311]; [@b48-copd-3-311]). The clinicians' misperceptions again suggest opportunities for education and potentially changes who and how patients are assessed for COPD.

A significant percent of the attendees recognized and reported a gap in their training about the diagnosis and management of COPD. Training related to COPD and its diagnosis through use of pre- and post-bronchodilator spirometry testing should begin in medical school ([@b55-copd-3-311]) and be supplemented in residency training and in continuing medical education. Physicians who had completed training within the past 15 years were no more likely than those completing training more than 15 year ago to report use of spirometry or reversibility testing to diagnose COPD, which suggests that more recent training is still not addressing this issue sufficiently. The ability to fit additional COPD training into the more limited training time available to NPs and PAs will require very careful consideration of their role in COPD management.

This study is not large. However, the results are comparable to those of previous larger studies of US physicians ([@b6-copd-3-311]). The generalizability of the results are limited by the inclusion of only 3 geographic sites and by the 37% of attendees who did not return the survey. It is also possible that the attendees had a special interest in COPD. However, this seems unlikely since COPD was only one of five chronic diseases covered during the one day session. Generalizability from the full sample may also be limited by the large number of non-physician clinicians in attendance, a percent significantly higher than in US clinic practice. For example, NP/PAs were less likely than physicians to report using reversibility testing in making the diagnosis of COPD.

In summary, COPD is the fourth leading cause of death in the US and among the top 10 reasons patients visit a family physician. While the data from this survey is encouraging in the rate of reported use of spirometry testing for COPD diagnosis, awareness of COPD guidelines and pessimism regarding the benefits of treating COPD, the infrequent use of reversibility testing for COPD diagnosis, and the over 40% of attendees who do not use and are not even aware of COPD guidelines should be the basis for a review of our medical and nursing education regarding COPD during initial training and in continuing education programs.

###### 

Demographics

  Type of health professional                                       Medical doctor   Nurse practitioner/Physician's assistant
  ----------------------------------------------------------------- ---------------- ------------------------------------------
  Median age                                                        50--59           40--49
  \% women                                                          42%              86%
  Median tears in practice                                          16--25           5--15
  Had spirometry in office                                          55%              55%
  Used reversibility or post bronchodilator testing for diagnosis   38%              23%
  Reports lack of knowledge as a barrier                            39 (22%)         33 (33%)

###### 

Use of guidelines with respondent characteristics

  Type of health professional        Medical doctor n = 178   Nurse practitioner/Physician's assistant n = 100   Has spirometry in office n = 148   Age \<50 n = 149   Age ≥50 n = 130
  ---------------------------------- ------------------------ -------------------------------------------------- ---------------------------------- ------------------ -----------------
  Uses GOLD or ATS COPD guidelines   56 (31%)                 34 (34%)                                           62 (42%)                           47 (32%)           42 (32%)
  Uses none or does not know         59 (33%)                 40 (40%)                                           43 (29%)                           59 (40%)           42 (45%)

###### 

Use of signs and symptoms and tests to diagnose COPD

  Type of training   Spirometry   Pre and post broncho-dilator   Symptoms(any of three)   Smoking history   Chest radiograph   Trial of corticosteroids   Trial of broncho-dilators
  ------------------ ------------ ------------------------------ ------------------------ ----------------- ------------------ -------------------------- ---------------------------
  MD n = 178         138 (78%)    56 (31%)                       120 (67%)                118 (66%)         109 (61%)          22 (12%)                   56 (31%)
  NP/PA n = 100      74 (74%)     23 (23%)                       61 (61%)                 59 (59%)          59 (59%)           7 (7%)                     23 (23%)

**Abbreviations:** MD, medical doctor; NP, nursing practitioner; PA, physician's assistant.

###### 

Perceived barriers in the diagnosis of COPD

  Type of health professional   Lack of specific symptoms   Failure of patients to recognize and report dyspnea   Multiple chronic conditions   Lack of knowledge and training   Lack of access to spirometry   Lack of effective treatment
  ----------------------------- --------------------------- ----------------------------------------------------- ----------------------------- -------------------------------- ------------------------------ -----------------------------
  MD n = 178                    35 (20%)                    85 (48%)                                              80 (45%)                      39 (22%)                         51 (29%)                       13 (7%)
  NP/Pas n = 100                22 (22%)                    50 (50%)                                              64 (64%)                      33 (33%)                         21 (21%)                       5 (5%)

**Abbreviations:** MD, medical doctor; NP, nursing practitioner; PA, physician's assistant.
